The Scripps Research Institute Lead Identification ... Assisting Scientists with Drug Discovery Through Screening-Based Research ...
The Lead Identification Division of Scripps Florida, in collaboration with other scientists at Scripps and around the world, identifies drug-like compounds that can help better understand and ultimately cure diseases such as cancer, diabetes, Alzheimer's and hepatitis.
How We Do It
By combining robotics, biology, chemistry and informatics, the Lead Identification Division is able to perform High-Throughput Screening, a robotic process that tests hundreds of thousands of drug-like compounds for biological activity both rapidly and economically. In addition we have the personnel and facilities to engage both pre- and post-HTS activities, including HTS assay development, cheminformatics, compound synthesis/procurement, compound QC (via LC-MS) and mechanism of action/profiling studies. We work with mammalian, yeast, insect, parasite and bacterial targets.
Since establishing operations in 2005, we have screened over 200 targets in over 235 primary campaigns to generate more than 80 million data points for both industrial and academic collaborations. Numerous scientific papers and presentations demonstrate our ability to produce excellent research-driven data. Our screening results have led to the development of over 70 bioactive molecular probes as novel drug targets for biomedical studies. Two probes have now been approved by the FDA as New Chemical Entities (NCEs) for clinical trials in the treatment of multiple sclerosis (MS) and cancer as licensed by Receptos and Cleave Biosciences. We also design and build novel screening technologies.
Working With Us
For academic collaborators, a popular way to access our expertise and facilities is through NIH-sponsored mechanisms. Industrial and academic collaborators can also directly sponsor specific screening activities. Please feel free to contact us if you have any questions or would like more information.